Cargando…
Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management
Immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 (PD-1) and its ligand PD-L1 and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibodies, are involved in T cell-mediated immune response augmentation and promote anti-tumor immunity. Cancer patients treated with combina...
Autores principales: | Liu, Ya, Zhang, Hao, Zhou, Li, Li, Weichun, Yang, Le, Li, Wen, Li, Kezhou, Liu, Xubao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959713/ https://www.ncbi.nlm.nih.gov/pubmed/33732647 http://dx.doi.org/10.3389/fonc.2021.627612 |
Ejemplares similares
-
Laparoscopic spleen-preserving distal versus central pancreatectomy for tumors in the pancreatic neck and proximal body
por: Zhang, Hao, et al.
Publicado: (2019) -
Neurologic adverse events of cancer immunotherapy
por: de Brito, Marcelo Houat
Publicado: (2022) -
Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
por: Li, Ying, et al.
Publicado: (2023) -
Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022) -
Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)